| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
MMP-7 16 nM (IC50) MMP-14 11000 nM (IC50) MMP-12 12000 nM (IC50) MMP-2 33000 (IC50) MMP-3 >100000 (IC50) MMP-8 >100000 (IC50) MMP-9 >100000 (IC50) MMP-13 >100000 (IC50)
MMP-7-IN-2 targets matrix metalloproteinase-7 (MMP-7, also known as matrilysin), a zinc-dependent endopeptidase involved in the degradation of extracellular matrix components including proteoglycans, fibronectin, and collagen. MMP-7 is implicated in various pathological processes including inflammation, tissue remodeling, and tumor progression. By selectively inhibiting MMP-7, MMP-7-IN-2 enables precise mechanistic studies of MMP-7 function without off-target effects on other MMPs. |
|---|---|
| ln Vitro |
In vitro, MMP-7-IN-2 demonstrates potent and selective inhibition of MMP-7 with an IC50 of 16 nM. The compound shows high selectivity for MMP-7 over other MMP family members, enabling precise mechanistic insights into MMP-7-driven processes. MMP-7-IN-2 inhibits MMP-7 activity in a concentration-dependent manner in biochemical assays using purified enzyme preparations.
|
| ln Vivo |
In vivo activity data for MMP-7-IN-2 are limited, as the compound is primarily studied in vitro. Based on its MMP-7 inhibitory mechanism, the compound is expected to modulate inflammatory responses and vascular-related diseases in animal models. However, detailed efficacy studies in animal models have not been extensively reported. The compound's potential for in vivo applications requires further investigation.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for MMP-7-IN-2 typically involves measuring MMP-7 activity using a fluorogenic peptide substrate. Purified recombinant human MMP-7 is incubated with varying concentrations of MMP-7-IN-2 (0.001-1000 nM) in assay buffer (e.g., Tris-HCl, pH 7.5, containing calcium and zinc ions) at 37°C for 30-60 minutes. The reaction is initiated by adding the substrate, and fluorescence is measured continuously. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing MMP-7 or involved in inflammatory responses are cultured and treated with MMP-7-IN-2 at concentrations ranging from 0.1-100 µM for 24-72 hours. MMP-7 activity is measured in cell lysates or conditioned media using activity assays. Extracellular matrix degradation is assessed by measuring matrix components. Inflammatory cytokine levels are measured by ELISA. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal studies for MMP-7-IN-2 have not been extensively reported. Based on the compound's mechanism as a selective MMP-7 inhibitor, potential in vivo studies would involve administration to mouse models of inflammation, vascular disease, or cancer via oral gavage, intraperitoneal injection, or intravenous injection at doses ranging from 1-50 mg/kg. MMP-7 activity would be assessed in tissues. Inflammatory markers and disease progression would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MMP-7-IN-2 have not been fully characterized. The molecular weight is 719.22 g/mol and the molecular formula is C₂₈H₄₀ClF₃N₆O₉S. The compound is supplied as a high-purity solid. Detailed pharmacokinetic parameters such as bioavailability, half-life, and protein binding have not been reported. Stability in solution may be limited and fresh solutions should be prepared for each experiment.
|
| Toxicity/Toxicokinetics |
Toxicology data for MMP-7-IN-2 are limited. As a research compound, it has not been systematically evaluated for safety. The compound's mechanism of MMP-7 inhibition suggests potential effects on tissue remodeling and wound healing, which would require careful safety assessment. Standard toxicological endpoints including cell viability, genotoxicity, and organ toxicity should be evaluated. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
MMP-7-IN-2 (compound 16) is a selective and potent inhibitor of MMP-7 with an IC50 of 16 nM. It is designed for studying MMP-7-driven processes including extracellular matrix remodeling, tissue repair, and tumor progression. The compound is valuable for research on inflammatory responses and vascular-related diseases. MMP-7-IN-2 is intended for research use only and is not approved for therapeutic applications.
|
| Molecular Formula |
C28H40CLF3N6O9S
|
|---|---|
| Molecular Weight |
729.165215492249
|
| Exact Mass |
728.221
|
| CAS # |
2848717-49-5
|
| PubChem CID |
168282091
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
48
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CC[C@@H](C(=O)O)NS(=O)(=O)C1=CC(=C(C=C1)Cl)C(F)(F)F
|
| InChi Key |
XHPNKAPWXFVQKQ-AEEVCGNZSA-N
|
| InChi Code |
InChI=1S/C28H40ClF3N6O9S/c1-13(2)10-20(25(42)37-23(14(3)4)26(43)35-15(5)24(33)41)36-22(40)12-34-21(39)9-8-19(27(44)45)38-48(46,47)16-6-7-18(29)17(11-16)28(30,31)32/h6-7,11,13-15,19-20,23,38H,8-10,12H2,1-5H3,(H2,33,41)(H,34,39)(H,35,43)(H,36,40)(H,37,42)(H,44,45)/t15-,19-,20-,23-/m0/s1
|
| Chemical Name |
(2S)-5-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (137.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3714 mL | 6.8571 mL | 13.7142 mL | |
| 5 mM | 0.2743 mL | 1.3714 mL | 2.7428 mL | |
| 10 mM | 0.1371 mL | 0.6857 mL | 1.3714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
